Welcome to Rubicon Genomics!
Rubicon Genomics is a leader in the development and commercialization of pre-analytical amplification methods that improve genetic, epigenetic, and expression analysis in research and clinical applications. Our amplified products are used in thousands of laboratories for analysis using Q-PCR, microarrays, and next-gen sequencing platforms.
Technology
Rubicon has developed platforms for amplification and standardization of nucleic acids that improve the performance of analytical platforms, including qPCR, microarrays, and next-gen sequencing. Our GenomePlex®, TransPlex®, and MethylPlex™ products enable many critical research and diagnostic applications that were previously impossible or unreliable due to variations in the quantity or quality of the starting research and clinical samples.
Research Products
We provide custom amplification and biomarker discovery services to the university, government, pharmaceutical and biotechnology markets. We have experience with virtually every source of DNA and application known to genomics and can rely upon this experience to adjust protocols, if necessary, to provide a superior product on a fixed schedule. In addition, we collaborate with companies and researchers who are developing better diagnostic tests for multiple analytes using Q-PCR, microarrays, and next-gen sequencing.
Diagnostic Products
Rubicon provides GenomePlex reagents and licenses to reference laboratories and diagnostics manufacturers to enable more effective patient testing, for example to facilitate more effective pre-implantation genetic diagnostics and cancer diagnostics.
MethylPlex™ is the diagnostic flagship of the Rubicon amplification platforms. We have discovered and licensed valuable methylation biomarkers to our diagnostic partners, as well as delivered simple, robust, automatable methylation assays for detection and management of cancer.
Rubicon News
- July 1, 2009 — BlueGnome to Distribute PicoPlex Technology from Rubicon Genomics
- June 30, 2009 — Rubicon Genomics Introduces PicoPlex Single Cell Whole Genome Amplification Kit
- May 28, 2009 — ZYGEM CORP SIGNS AGREEMENT TO INCORPORATE ITS BREAKTHROUGH DNA EXTRACTION TECHNOLOGY INTO RUBICON’S RESEARCH AND DIAGNOSTIC PRODUCTS
- Jan. 12, 2009 — Rubicon Genomics Announces a Licensing Agreement with Abbott to Develop and Commercialize DNA Methylation Cancer Tests
- Oct. 13, 2008 — Rubicon Provides Genome Amplification for the Cancer Genome Atlas Project
- Jan. 22, 2007 — Rubicon Genomics Enters into Collaboration Agreement with OncoMethylome Sciences
- Dec. 13, 2006 — Rubicon Licenses TransPlex WTA to Sigma-Aldrich
- Feb. 27, 2006 — Rubicon Genomics and Asterand plc Sign Biomarker Partnership
- Feb. 17, 2006 — Rubicon Genomics licences WGA services rights to Sigma-Aldrich
- Feb. 10, 2006 — New Single Cell WGA Kit is Launched by Sigma-Aldrich
- Oct. 31, 2005 — Rubicon Genomics and Abbott Molecular to Co-Develop Simple Non-Invasive Cancer Diagnostics
- Sept. 8, 2005 — Rubicon Genomics Launches the TransPlex™ Whole Transcriptome Amplification Kit for Improved Expression Profiling from Fixed and Unfixed Tissue
- July 21, 2005 — Rubicon Genomics Signs Agreement with the Genome Institute of Singapore for Retrospective Studies of Serum
- Feb. 7, 2005 — Rubicon Genomics Continues to Strengthen its Board of Directors
- Jan. 11, 2005 — Rubicon Genomics Adds New Member to its Board of Directors
- Jan. 4, 2005 — Rubicon Genomics Receives $250K In Bridge, Eyes $1.2M Overall
- Dec. 14, 2004 — Rubicon Genomics Develops New Cancer Detection Technology
- Oct. 4, 2004 — Sigma-Aldrich and Rubicon Genomics announce GenomePlex™ Whole Genome Amplification licensing agreement
- Aug. 6, 2003 — Rubicon Genomics Provides Genome Amplification for The Wellcome Trust Sanger Institute
- Feb. 10, 2003 — Rubicon Launches OmniPlex™ Whole Genome Restoration of Damaged DNA From Pathology and Other Samples
- Dec. 16, 2002 — Rubicon Genomics, Inc. Launches Omniplex™ Whole Genome Amplification Services